Top Markets
Coin of the day
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
株式のランク #25246
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
株価
$23.57
最終同期: 2026-08-20
時価総額
$51.76M
変化(1日)
-0.08%
変化(1年)
289.59%
US
取引 Apollomics, Inc. (APLM)

カテゴリー

Apollomics, Inc.(APLM)の配当利回りの履歴
Apollomics, Inc.(銘柄コード: APLM)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Apollomics, Inc.(APLM)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)